FGF19 and hepatocellular carcinoma: To determine whether the GSK3β/β-catenin signaling plays an essential role in FGF19-induced EMT in HCC cells, we inactivated GSK3β function using a GSK3β inhibitor TWS119, which leads to reduced β-catenin phosphorylation and induces nuclear translocation of β-catenin [33].